Funded Tech Companies
Alentis Therapeutics
Headquartered in Allschwil, Alentis Therapeutics raised its funding from InnoBio Fund, Jeito Capital and BB Pureos Bioventures.
Company Overview
Company Name
Alentis Therapeutics
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
Hegenheimermattweg 167A
Allschwil, 4123
CH
Allschwil, 4123
CH
Phone
Undisclosed
Website
Email Address
Company Background Information
Overview
Alentis Therapeutics is a clinical-stage biopharmaceutical company developing breakthrough treatments for cancer and fibrotic diseases. Claudin-1 (CLDN1) is a member of the tight junction proteins family. During disease pathogenesis, CLDN1 expression is up-regulated and exposed outside of the tight junction. Exposed, non--tight junctional, CLDN1 drives carcinogenic and fibrogenic signaling in different organs.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
4/13/2023
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Roberto Iacone
Chief Medical Officer
Luigi Manenti
Chief Operating Officer
Markus Meyer
Chief Technical Officer
Greg Elson
Founder
Thomas Baumert
Company Investors
- InnoBio Fund
- Jeito Capital
- BB Pureos Bioventures
- Bpifrance
- RA Capital Management
- Novo Holdings
- Schroders Capital
Browse more funded tech companies:
Share this article
About Our Venture Capital Database
The company data above is provided by VentureDeal.com, a leading provider of venture capital transaction data.
Additional Resources for Entrepreneurs